Cargando…

Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses

BACKGROUND: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are a mainstay treatment for hormone receptor-positive breast cancer. While their principal mechanism is inhibition of cancer cell proliferation, preclinical and clinical evidence suggests that CDK4/6i can a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Amrendra, Ramani, Vijay, Bharti, Vijaya, de Lima Bellan, Daniel, Saleh, Nabil, Uzhachenko, Roman, Shen, Chengli, Arteaga, Carlos, Richmond, Ann, Reddy, Sangeetha M, Vilgelm, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231009/ https://www.ncbi.nlm.nih.gov/pubmed/37230537 http://dx.doi.org/10.1136/jitc-2022-006019

Ejemplares similares

Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade
por: Luo, Yan, et al.
Publicado: (2023)

Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity
por: Zheng, Ming
Publicado: (2023)

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
por: Lai, Anne Y, et al.
Publicado: (2020)

Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
por: Abe, Shinya, et al.
Publicado: (2022)

Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models
por: Kansal, Vikash, et al.
Publicado: (2023)

Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
por: Zhu, Shaoming, et al.
Publicado: (2021)

Correction: Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses
Publicado: (2023)

CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma
por: Zhou, Quan, et al.
Publicado: (2020)

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
por: Beattie, Jason, et al.
Publicado: (2021)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
por: Chen, Shih-Hsun, et al.
Publicado: (2021)

Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer
por: Busenhart, Philipp, et al.
Publicado: (2022)

Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice
por: Küçükköse, Emre, et al.
Publicado: (2022)

In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis
por: Kim, Seohyun, et al.
Publicado: (2021)

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
por: Jeong, Seongju, et al.
Publicado: (2021)

Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade
por: Xu, Lijun, et al.
Publicado: (2022)

Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8(+) T cell antitumor immunity
por: Li, Anqi, et al.
Publicado: (2022)

Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions
por: Bauché, David, et al.
Publicado: (2020)

PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity
por: Koller, Paul, et al.
Publicado: (2023)

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
por: Subudhi, Sumit K, et al.
Publicado: (2021)

Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
por: Yoshida, Takashi, et al.
Publicado: (2021)

Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity
por: Nawaf, Maher G., et al.
Publicado: (2017)

Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
por: Ou, Da-Liang, et al.
Publicado: (2021)

CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma
por: Zhang, Ruonan, et al.
Publicado: (2023)

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade
por: Patin, Emmanuel C, et al.
Publicado: (2022)

In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade
por: Mao, Chenkai, et al.
Publicado: (2022)

Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial
por: Ott, Patrick A, et al.
Publicado: (2021)

COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
por: Holmstroem, Rikke Boedker, et al.
Publicado: (2022)

T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma
por: Wang, Xiaobin, et al.
Publicado: (2023)

Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner
por: Thakkar, Dipti, et al.
Publicado: (2022)

High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4(+) and CD8(+) neoantigen-specific T cells to promote antitumor immunity
por: Hernandez, Rosmely, et al.
Publicado: (2021)

Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression
por: Pierini, Stefano, et al.
Publicado: (2021)

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
por: Sheng, Hailong, et al.
Publicado: (2020)

Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects
por: Veeramachaneni, Ratna, et al.
Publicado: (2021)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Lau, Doreen, et al.
Publicado: (2021)

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
por: Zheng, Ming
Publicado: (2022)

CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models
por: Ye, Jian, et al.
Publicado: (2023)

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
por: Gomez-Roca, Carlos, et al.
Publicado: (2022)

Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response
por: Qi, Xiaoqiang, et al.
Publicado: (2020)

Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization
por: Jagodinsky, Justin C, et al.
Publicado: (2022)

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
por: Fu, Yu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t9p37n29radkg3ihsrtd0grt4a